The most common sites for Paget's disease of the spine are the sacrum followed by the lumbar spinel, but paraparesis is more common with dorsal involvement. Over 100cases of dysfunction of the spinal cord or cauda equina secondary to Paget's disease of the vertebral column have been described since it was first reported by Wyllie 2. We report a patient with paraparesis secondary to Paget's disease of the dorsal vertebrae with complete myelographic obstruction, who was treated medically with disodium etidronate.
Case report
A 79-year-old man was admitted with a 4-year history of progressive weakness of the legs, and at the time of admission was able to walk only about half a mile with the aid of a stick. The weakness had started in the left leg, but 12 months before admission had begun to involve the right. There was no paraesthesia, nor any sphincter disturb-ance. Four years ago, he was discovered to have non-insulin-dependent diabetes mellitus.
On examination his blood pressure was 140/ 90 mmHg and the pulse was regular at 76 beats per minute. There were no abnormalities in the chest or abdomen. There was a moderate spastic paraparesis, more marked on the left than the right, with wasting and weakness of the left quadriceps and absent ankle jerks. The knee jerks were exaggerated. Joint position sense was markedly reduced in both feet and there was decreased light touch and pinprick sensation up to the knee. There was no spinal tenderness. Fundi showed background diabetic retinopathy.
Investigations: Urine examination showed no proteinuria. Haemoglobin was 13.5g/dl, white blood count 8.1 x 10 9/1, platelets 297 x 10 12/1, ESR 8mm/h, blood urea 5.4 mmol/l, creatinine 80 Jlmol/l, normal electrolytes, blood glucose 8.2 mmol/l, urinary hydroxyproline, 0.54mmol/24 hours (normal range 0.04-0.13), calcium 2.40mmol/l, organic phosphate 1.29mmol/l, total protein 71mg/l, albumin 44 gIl, total bilirubin 12Jlmol/l, alkaline phosphatase 551iu/l (normal range 30-85), aspartate transaminase 22 iu/l, gamma-GT 27 iu/l (normal 65) and aspartate aminotransferase 10-50 iu/I. Nerve conduction studies confirmed the presence of motor neuropathy of the left femoral nerve (amyotrophic diabetic neuropathy) and distal sensory neuropathy (presumably diabetic) of the lower limbs. Dorsal spine X·rays demonstrated multifocal abnormalities throughout the dorsal spine, most marked A CAT brain scan was normal. A myelogram showed complete obstruction to the passage of contrast at the level ofD6, where there was an extradural mass indenting and compressing the cord principally from the posterior and lateral aspects. The vertebral bodies at this level were partially destroyed and the pedicles ofD5 and D6 were also involved. A small soft tissue mass was noted in addition on both sides, indenting the dural reflection. The disc space was indistinct at this level. CSF showed no cells but protein was 3000mgjl.
A bone scan ( Figure 1 ) showed severe involvement of the upper spinal vertebrae (approximately D4, D5 and D6) and their appendages, including the spinal transverse processes, with changes in the sacrum and sacroiliac joints.
A bone biopsy of D4jD5 confirmed the diagnosis of Paget's disease of bone without any evidence of sacromatous changes. Treatment: He was treated with disodium etidronate 200 mg a day for 6 months. This led to remarkable symptomatic improvement with an increase in muscle power. The serum alkaline phosphatase fell to 156iujl after 5 months and to 85 iujl after 7 months. The urinary hydroxyproline also fell to 0.09 mmolj24 hours 6 months after start of treatment. A year later, the patient remains well and serum alkaline phosphatase and urinary hydroxyproline have stayed within the normal range.
Discussion
The presence of a paraspinal soft tissue mass and the indistinction of the intervertebral disc spaces at D4-D6 in our patient are unusual but recognized features of Paget's disease of the vertebraev". This may be confused with Pott's disease of the spinel.
Until recently, the only effective treatment for spinal cord compression secondary to Paget's disease of the vertebrae has been surgical decompression, especially where myelographic evidence for compression is found", However, one of the main difficulties with surgical decompression is locating the optimum site for it 6 because of the multiple sites of involvement, thus necessitating multiple, concurrent or successive laminectomies 7 . 8 . During recent years, calcitonin, mithramycin and diphosphonates have proved to be effective treatment for Paget's disease? and all three drugs have been successfully used in the management of paraparesis associated with Paget's disease of the vertebrae 1o -19 • In a recent aeries", treatment for 3-87 months (mean 25 months) with calcitonin or with diphosphonates produced marked clinical improvement in 7 of8 patients with paraparesis associated with Paget's disease of the vertebrae. The same authors also reviewed 19 additional case reports 1 1 -19 from the English and French literature of the medical treatment of the same condition. Out of the total 27 patients, 16 were treated with calcitonin, 4 with diphosphonates and 7 with a combination or sequence of these. Twenty-four (89%) improved and 22 (81%) had either marked or complete reversal of their abnormal neurologic symptoms and signs. Two patients had only marginal improvement and 3 showed no response, but no patient became worse.
It would appear that medical treatment can be as effective as surgical intervention. In a large series'' of 90 cases, 64 of whom had been explored surgically, improvement occurred in 55 of the latter (85%). Two patients were unchanged and one was made worse. Six patients underwent more than one laminectomy. There were 7 (11%) operative deaths.
It appears from the above comparison and our case report that the results of medical treatment are as good as, ifnot better than, those obtained with surgical decompression. However, future experience will be needed to determine the length of treatment and how recurrence can be avoided. Greenwood the statement that research is to be regarded as a good thing -that more research tends to make clinical practice more ethical, not less. He quoted the nineteenth-century French physiologist Claude Bernard: 'It i~our duty and our right to perform an experiment on man whenever it can save his life, cure him, or gain him some personal benefit', and then proceeded to examine in terms of this statement some of the ethical problems that research may pose, with particular reference to children.
Referring to the working group set up recently by the Institute of Medical Ethics, he remarked that one of its recommendations had been that research should not be undertaken on children unless there was no other reliable or relevant route to the same end. An analogous American institution had similarly recommended that, since research should be not haphazard but be 'a systematic investigation to increase the sum of know ledge', it must be scientifically both sound and significant: any committee concerned with ethical questions must have proper scientific advice. He then addressed himself to the moral complexities introduced by 'non-therapeutic' as opposed to therapeutic research, Therapeutic reo search implies a procedure involving a particular patient already suffering from a disease or malfunction, and he pointed out that in such cases it is the procedure (medical treatment, intervention, etc.) that may properly be regarded as 'therapeutic' rather than the research of which it may form a part: in the same sense nearly all clinical therapy is, in intention, 'therapeutic' though, lacking a research basis, much of it is often scientifically haphazard. 'Innovative therapy' usually implies that a new procedure is being employed, and it is generally agreed that in such cases the ratio of envisaged benefit to risk should be carefully weighed. The benefit side of the equation in a new method should be at least as great as that obtaining in established methods of treatment.
But the word 'benefit' shifts the discussion into the area of 'non-therapeutic research': benefit to whom? A conflict may arise between the likely benefit (if any) of a new procedure to an individual child and the putative good to other children. It is in the context of this moral dilemma that the subsidiary questions -What, with a child, may constitute 'informed consent'? Is 'proxy consent' by parents a valid concept? -also become particularly difficult. Doctors, by the nature of their own zeal, are inevitably apt to influence patients or patients' families: it is also undeniable that those involved in a research programme of innovative therapy stand to gain personal acclaim thereby, particularly with 'glamorous' procedures such as heart transplants.
To illustrate his earlier remarks, therefore, Dr Shinebourne outlined the recent history of treatment for transposition of the great arteries -the condition in which venous blood that should be reoxygenated bypasses the lungs, which then only receive already oxygenated blood: a 'blue baby' syndrome. Between 1970 and 1980, treatment by what was known as Mustard's operation produced a mortality rate of 10% in the more straightforward cases, rising to 25% in cases complicated by a large aperture between the ventricles. A different operation, switching the major blood vessels, was introduced in 1976but at first had a Report of meeting of Open Section, 10 February 1986 0141-0768/87/ 050321·03/$02.00/0 e 1987 The Royal Society of Medicine
